

Press Release - June 20, 2023

EG 427 announces that Dr. Greg Sarek, VP Research will be presenting at the 3rd annual Next Generation Gene Therapy Vectors conference June 27-29, 2023, Boston MA

Paris, France, June 20, 2023 – EG 427, a biotechnology company leading the development of pinpoint DNA medicine solutions, announces today that Dr. Greg Sarek, VP Research, will be presenting the company's unique non-replicative HSV-1 vector platform during the 3rd annual Next Generation Gene Therapy Vectors.

Focusing on ways to identify and adapt novel gene therapy vector properties to progress safer, targeted and efficacious therapies, the conference will host Dr. Greg Sarek to give an in-person presentation on Tuesday, June 27, at 3:10 pm ET at the conference venue in Boston. His talk will elaborate on the power of non-replicative HSV-1 gene delivery platform to address local chronic neuronal disorders.

Details on the conference website [here](#) and registration for the conference is open [here](#)

To request a one-on-one meeting with our delegate, please contact info@eg427.com

About EG 427

EG 427 has developed a unique, non-replicative Herpes Simplex Virus type 1 (nrHSV-1) based vector platform. It delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes. We take advantage of it to design new treatments of peripheral nervous system disorders and beyond.

Our lead asset, EG110A, targets the silencing of type-C sensory neurons. It is first being developed in urology indications. Our earlier stage products are focused on modifying the neurotransmission of other subsets of neurons. Furthermore, we are building the necessary manufacturing efficiency to bring genomic medicine to more prevalent, high medical need indications.

Our HQ and labs are located in Paris, France.

For more information:

 check our website at www.eg427.com

follows us on  at www.linkedin.com/company/eg427/

Contacts:

Company


Philippe Chambon, M.D., Ph.D.

EG 427 Founder and CEO

US: 415-533-9359

FR: +33 7 70 02 22 08

philippe@eg427.com



EG 427

PINPOINT GENE THERAPY

Press Release - June 20, 2023

Media

US

Selina Husain / Robert Flamm, Ph.D.
Burns McClellan, Inc.
shusein@burnsmc.com
[mailto:/ rflamm@burnsmc.com](mailto:rflamm@burnsmc.com)

EU

Sophie Baumont
Rose Piquante Consulting
sophie.baumont@rosepiquante-consulting.com

